Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
By Lori Solomon HealthDay Reporter
MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of Endocrinology, hosted by the European Society of Endocrinology from May 11 to 14 in Stockholm.
Angelica Lindén Hirschberg, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues assessed early response to fezolinetant in terms of frequency and severity of moderate-to-severe VMS. The analysis included 453 women unsuitable for hormone therapy participating in the 24-week placebo-controlled DAYLIGHT study.
The researchers found that compared with those taking placebo, participants treated with fezolinetant (45 mg) had a greater reduction in the daily mean change in frequency of moderate-to-severe VMS from baseline through the first week of treatment (day 7 least squares mean difference, –2.20). There was a decrease observed in VMS frequency from days 1 to 6, with the strongest decrease seen during the first three days. Additionally, fezolinetant was associated with greater reduction in the daily mean change in VMS severity from days 2 to 7 compared with placebo (day 7 least squares mean difference, –0.17). Through week 24, improvements in VMS frequency and severity were sustained. There were no safety signals of concern reported through week 24.
"An effect on VMS frequency was seen as early as day 1 and maintained through the 24-week placebo-controlled period, demonstrating a rapid onset of action and sustained efficacy with fezolinetant treatment," the authors write.
The study was funded by Astellas Pharma, the manufacturer of fezolinetant.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Acupuncture Reduces Endocrine Symptoms, Hot Flashes in Breast Cancer
MONDAY, June 24, 2024 -- A 10-week acupuncture intervention significant reduces endocrine symptoms and hot flashes among women with breast cancer receiving endocrine therapy (ET)...
Chronic Kidney Disease Tied to Tooth Loss After Menopause
MONDAY, June 17, 2024 -- In postmenopausal women, chronic kidney disease (CKD) may be associated with tooth loss, according to a study published online June 11...
ENDO: Early Menopause Tied to Heightened Risk for Breast, Ovarian Cancer
TUESDAY, June 11, 2024 -- Women with early menopause have a two times greater risk for breast cancer and a nearly four times higher risk for ovarian cancer, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.